Additional file 1: Table S1. of Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer

Association between clinicopathological data and SOX2 gene status in NSCLC tumors. (PDF 101 kb

Simplified Determinations of the “True” Creatinine Concentration in Serum and Urine

Peer Reviewe

Association of FAM46A VNTR genotypes with NSCLC in Croatian and Norwegian subjects.

<p>p^U: unadjusted p-value,</p><p>p^g: p-value adjusted for gender,</p><p>p^ag: p-value adjusted for age and gender,</p><p>p^ags: p-value adjusted for age, gender and smoking status,</p><p>N: number of alleles or genotypes include in the analysis, LFG: Low frequency genotypes (ab+ac+ad+ae+bf+cf+af+ee+ef+ff), CI: confidence interval, OR: Odds ratio</p><p>Association of FAM46A VNTR genotypes with NSCLC in Croatian and Norwegian subjects.</p

Genotypes frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.

<p>N: frequency of genotypes/alleles per group, n: total number of alleles per group.</p><p>Genotypes frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.</p

Alleles frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.

<p>N: frequency of genotypes/alleles per group, n: total number of alleles per group</p><p>Alleles frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.</p

Proportion of patients with none, one, or two (or more) biomarkers (WBC count, CRP, IL-6 and fibrinogen) in the upper quartile of the COPD distribution, at baseline (left bars) and after one year follow up (right bars).

<p>For further explanations, see text.</p

Box plot (log scale) of the different biomarkers determined at baseline in COPD patients, smokers with normal lung function and nonsmokers.

<p>For further explanations, see text.</p

Summary of logistic regression for persistent systemic inflammation (defined as in upper quartile at both visits for at least 2 biomarkers).

<p>Statistically significant factors are highlighted in bold. For further explanations, see text.</p

Comparison of baseline demographics, clinical, physiological and imaging characteristics of COPD patients with none or two (or more) biomarker levels in the upper quartile of the COPD distribution both at baseline and at one year follow-up.

<p>NS: non-significant.</p

Additional file 1: of Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease

The Appendix. (DOCX 90 kb